WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...